Association of mortality and aspirin prescription for COVID-19 patients at the Veterans Health Administration

2/11 Pre-Exposure Prophylaxis study (treated before exposed to the virus)

Osborne et al., PloS ONE, doi:10.1371/journal.pone.0246825 (Peer Reviewed)
Association of mortality and aspirin prescription for COVID-19 patients at the Veterans Health Administration

Source PDF Share Tweet

Retrospective PSM analysis of pre-existing aspirin use in the USA, showing lower mortality with treatment.

Osborne et al., 2/11/2021, retrospective, propensity score matching, USA, North America, peer-reviewed, 6 authors.

risk of death, 59.4% lower, RR 0.41, p < 0.001, treatment 272 of 6300 (4.3%), control 661 of 6300 (10.5%), odds ratio converted to relative risk, 30 days, PSM.

risk of death, 60.5% lower, RR 0.40, p < 0.001, treatment 170 of 6814 (2.5%), control 427 of 6814 (6.3%), odds ratio converted to relative risk, 14 days, PSM.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.

All 7 studies All Outcomes

Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.

Submit